Gastrointestinal health has emerged as one of the most consequential and rapidly expanding areas in global healthcare and functional nutrition.
The scale of the challenge is considerable: digestive diseases account for an estimated 7.32bn incident cases globally, with 2.86bn prevalent cases recorded across populations.1 More than 40% of people worldwide suffer from chronic gastrointestinal problems, making gut dysfunction one of the most widespread and underserved health concerns of our time.2
Reflecting the urgency of this demand, the Gut Health Nutraceuticals Market was valued at $12.24bn in 2024, underscoring the significant commercial momentum behind preventive gastrointestinal solutions.3
At the root of many of these conditions lies a common pathological driver: gut inflammation. Chronic intestinal inflammation weakens the structural integrity of the gut lining, disrupts normal digestive processes and creates conditions that predispose individuals to more serious disorders.4
When left unaddressed, it can promote the development of debilitating conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), both of which carry substantial burdens for patients and healthcare systems alike.5
As a result, there is a growing imperative for solutions that support gastrointestinal health at its biological foundations: targeting inflammation, barrier function and immune regulation.
Functional botanicals for gut optimisation
Within this expanding focus on digestive health, ingredient innovation has increasingly shifted toward targeted, mechanism-driven support. The functional nutrition industry is moving beyond broad digestive support claims toward ingredients designed to act on specific and measurable aspects of gut physiology – including mucosal integrity and immune regulation.
Plant-derived bioactive compounds are particularly well positioned for this transition. Dissimilar to single-target pharmaceutical agents, botanical extracts frequently engage multiple biological pathways simultaneously, making them well suited to the inherent complexity of gastrointestinal function.
The gut is not a simple system; it is the site of continuous interaction between epithelial cells, immune compartments and trillions of microbial organisms, and dysregulation in any one of these dimensions tends to propagate across the others.
Among the most relevant ingredient categories in this context are olive-derived polyphenols and triterpenes. Research suggests that specific combinations of these compounds may act synergistically in modulating inflammatory and oxidative stress-related pathways.6
This dual activity is particularly relevant to gut health, where oxidative damage and inflammatory signaling are deeply intertwined drivers of barrier dysfunction.
As scientific understanding of the gut-microbiome matures, market expectations for ingredients in this space are becoming more stringent. Natural origin and traditional use, while still valuable, are no longer sufficient to establish credibility.
Standardisation, mechanistic plausibility and evidence from controlled studies are now the benchmarks against which ingredients are evaluated by health brands, regulatory bodies and increasingly well-informed consumers.
Olive-derived polyphenols and triterpenes
Oligut™ is a branded botanical ingredient developed by Natac, derived from the leaves and fruit of Olea europaea L., the Mediterranean olive tree.
It is built around a patent-protected combination of olive polyphenols and triterpenes, selected and standardised for their demonstrated synergistic activity as anti-inflammatory agents and in protection against oxidative stress. It’s a gastrointestinal ingredient designed to act simultaneously on inflammation, barrier integrity and immune regulation.
The development reflects Natac’s broader scientific philosophy: transforming the well-characterized bioactive potential of olive-derived compounds into standardised, reproducible ingredient systems that meet the rigorous demands of modern functional nutrition.
Backed by multiple pre-clinical studies conducted in models with high translational relevance to humans, Oligut represents a new generation of evidence-informed botanical support for the gastrointestinal market – one that meets the sector’s growing demand for ingredients that are both scientifically substantiated and naturally derived.
Researched scientific evidence
The biological rationale behind Oligut has been substantiated through several pre-clinical in vivo and in vitro studies, providing mechanistic insight across each of its four target axes.
When it comes to intestinal barrier integrity, Oligut supplementation was associated with significantly higher plasma mannitol concentrations, indicating improved nutrient absorption and reduced intestinal permeability.7
At the molecular level, the extract rescued and enhanced expression of CDH1, the gene encoding the epithelial adhesion protein E-cadherin, in a model of chronic inflammation, reflecting the active restoration of intercellular junctions rather than merely the prevention of further degradation.7
In the area of immune modulation, studies in LPS-challenged animals demonstrated that Oligut helped regulate the systemic inflammatory response, preventing the immune overreaction that contributes to chronic tissue damage.
Animals receiving the extract also showed a protective effect against inflammation-induced immune suppression, contributing to a faster recovery of normal lymphocyte counts following immune challenge.8
Translating scientific evidence into gut health innovation
The pre-clinical evidence provides a scientific basis signifying the potential role of Oligut in relation to the interconnected biological mechanisms associated with gastrointestinal function. Its value to the market, however, extends beyond the data itself.
Through rigorous standardisation of its bioactive profile and reproducible extraction and formulation processes, Oligut enables health brands and manufacturers to integrate a well-characterised gut health ingredient into their products with confidence and reduced development complexity.
With a recommended dosage of 200mg per day for food supplement applications, it is designed for practical formulation across a broad range of delivery formats, including capsules, tablets, softgels, gummies and stick packs.
This versatility is particularly relevant as gut health expands beyond traditional supplement categories into functional foods, beverages and personalised wellness solutions. Brands operating in this space face growing pressure to substantiate their positioning with mechanistic credibility and structured scientific data.
Oligut is positioned within this context as a standardised, patent-protected ingredient system, combining a targeted formulation approach with the accessibility and scalability that modern markets demand.
In a category defined by complexity and consumer skepticism, Oligut offers an ingredient supported by a clear biological rationale, a structured body of research and the formulation flexibility to meet the evolving demands of the market.
References
- Wang, Y. et al. Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019. Gastroenterology. 2023; 165(3), 773-783.
- Sperber, A.D.; et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160(1), 99-114.
- Gut Health Nutraceuticals Market by Product, Form, Distribution Channel – Global Forecast to 2030. Report no. 5910264, 2025, 360iResearch.
- Lechuga, S.; et al. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim Biophys Acta Mol Cell Res. 2017; 1864(7), 1183-1194.
- Pérez de Arce, E. et al. Gastroenterol Hepatol, 2022, 45(1), 66-76.
- Patent: Quintela et al. 2019. Combination of pentacyclic triterpenes and polyphenols and derivatives thereof. (US 10,376,529 B2).
- Liehr, M.; et al. Olive oil bioactives protect pigs against experimentally-induced chronic inflammation independently of alterations in gut microbiota. PLoS One. 2017; 12(3):e0174239;
- Cangiano, L.R.; et al. Induction of leaky gut by repeated intramuscular injections of indomethacin to preweaning Holstein calves. J Anim Sci. 2019; 97(10), 4349-4361.
